Zobrazeno 1 - 10
of 220
pro vyhledávání: '"Emily K. Bergsland"'
Autor:
Teresa S. Wang, MD, Emily K. Bergsland, MD, Ruth Zhang, MD, Kai Ihnken, MD, Kirsten Tolstrup, MD
Publikováno v:
JACC: Case Reports, Vol 2, Iss 1, Pp 1-5 (2020)
We describe a case of atypical carcinoid heart disease. A 62-year-old woman with well-differentiated neuroendocrine tumor metastatic to the liver and lymph nodes presented with recurrent unilateral pleural effusions and lower extremity edema. Multimo
Externí odkaz:
https://doaj.org/article/318ba02c01194cafaeb5e94f32188d36
Autor:
David B. Donner, Dan T. Ruan, Kan Toriguchi, Emily K. Bergsland, Eric K. Nakakura, Meng Hsun Lin, Ricardo J. Antonia, Robert S. Warren
Publikováno v:
Translational Oncology, Vol 12, Iss 3, Pp 550-560 (2019)
PURPOSE: Prognostic schemes that rely on clinical variables to predict outcome after resection of colorectal metastases remain imperfect. We hypothesized that molecular markers can improve the accuracy of prognostic schemes. METHODS: We screened the
Externí odkaz:
https://doaj.org/article/51bb1daf9ad9461488607c00b9b1ca1a
Autor:
Nitya Raj, Jennifer A. Chan, Stephanie J. Wang, Rahul R. Aggarwal, Susan Calabrese, April DeMore, Lawrence Fong, Jennifer Grabowsky, Thomas A. Hope, Kanti Pallav Kolli, Claire K. Mulvey, Pamela N. Munster, Kimberly Perez, Sippy Punn, Diane Reidy-Lagunes, Sofia Von Fedak, Li Zhang, Emily K. Bergsland
Publikováno v:
British Journal of Cancer.
Autor:
Jennifer R Eads, Thorvardur R Halfdanarson, Tim Asmis, Andrew M. Bellizzi, Emily K Bergsland, Arvind Dasari, Ghassan El-Haddad, Michael Frumovittz, Joshua Meyer, Erik Mittra, Sten Myrehaug, Eric Nakakura, Nitya Raj, Heloisa P Soares, Brian Untch, Namrata Vijayvergia, Jennifer A Chan
Publikováno v:
Endocrine-Related Cancer.
High grade neuroendocrine tumors (G3 NET) and neuroendocrine carcinomas (NEC) are a rare disease entity for which there is a limited amount of prospective data available. It has also been relatively recent that a distinction has been made between G3
Autor:
Erica S. Tsang, Rahul R. Aggarwal, Mallika S. Dhawan, Emily K. Bergsland, Edwin A. Alvarez, Susan Calabrese, Romain Pacaud, Jose Garcia, Delaire Fattah, Scott Thomas, Jennifer Grabowsky, Mark M. Moasser, Pamela N. Munster
Publikováno v:
Cancer Research Communications. 2:570-576
The PI3K pathway may be a potential mechanism to overcome cisplatin resistance. We conducted a phase Ib trial of alpelisib and cisplatin for patients with solid tumor malignancies with planned dose expansion in HPV-associated tumors. The primary obje
Autor:
Pamela N. Munster, Mark M. Moasser, Jennifer Grabowsky, Scott Thomas, Delaire Fattah, Jose Garcia, Romain Pacaud, Susan Calabrese, Edwin A. Alvarez, Emily K. Bergsland, Mallika S. Dhawan, Rahul R. Aggarwal, Erica S. Tsang
The PI3K pathway may be a potential mechanism to overcome cisplatin resistance. We conducted a phase Ib trial of alpelisib and cisplatin for patients with solid tumor malignancies with planned dose expansion in HPV-associated tumors. The primary obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5185da53f97a26f3cf85290739ff67de
https://doi.org/10.1158/2767-9764.c.6550920.v1
https://doi.org/10.1158/2767-9764.c.6550920.v1
Autor:
Pamela N. Munster, Mark M. Moasser, Jennifer Grabowsky, Scott Thomas, Delaire Fattah, Jose Garcia, Romain Pacaud, Susan Calabrese, Edwin A. Alvarez, Emily K. Bergsland, Mallika S. Dhawan, Rahul R. Aggarwal, Erica S. Tsang
A) Rationale for study drug dose interruption or reduction; B) Rationale for cisplatin dose interruption or reduction; C) Cisplatin dose intensity, stratified by dose level
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15538f083c9f21c5743c59ccfc7bbc42
https://doi.org/10.1158/2767-9764.22545363.v1
https://doi.org/10.1158/2767-9764.22545363.v1
Autor:
Eric K. Nakakura, Yucheng Wang, Danny Lee, Emily K. Bergsland, Alan P. Venook, Robert S. Warren, David B. Donner, Byron Hann, Grace E. Kim, Gregory S. Ducker, Kevan M. Shokat, Melanie Regan, Henry VanBrocklin, Jason Wang, Katherine Yang, Michael S. German, Chester E. Chamberlain
Pharmacodynamic studies of everolimus and sapanisertib treated PDX-PNETs using Western blot analysis of mTOR pathway targets.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02f39745bff86729f9eb105fc1438884
https://doi.org/10.1158/1535-7163.22510209.v1
https://doi.org/10.1158/1535-7163.22510209.v1
Autor:
Eric K. Nakakura, Yucheng Wang, Danny Lee, Emily K. Bergsland, Alan P. Venook, Robert S. Warren, David B. Donner, Byron Hann, Grace E. Kim, Gregory S. Ducker, Kevan M. Shokat, Melanie Regan, Henry VanBrocklin, Jason Wang, Katherine Yang, Michael S. German, Chester E. Chamberlain
Patients with pancreatic neuroendocrine tumors (PNET) commonly develop advanced disease and require systemic therapy. However, treatment options remain limited, in part, because experimental models that reliably emulate PNET disease are lacking. We t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27a024dff6751a82dfeb5466906ffc66
https://doi.org/10.1158/1535-7163.c.6539538.v1
https://doi.org/10.1158/1535-7163.c.6539538.v1
Autor:
Stephanie J. Wang, Julia Whitman, Alan Paciorek, Bryan Khuong Le, Eric K. Nakakura, Spencer C. Behr, Nancy Joseph, Li Zhang, Thomas A. Hope, Emily K. Bergsland
Publikováno v:
Journal of Neuroendocrinology. 35